甲氨蝶呤治疗类风湿关节炎不同给药方式探讨

2018-10-15 蜜蜂大夫 蜜蜂大夫

甲氨蝶呤是一种人工合成化合物,为叶酸结构类似物,通过竞争性地抑制二氢叶酸(FH2)与二氢叶酸还原酶(DHFR)的结合,降低细胞内可被利用的亚叶酸(FH4)含量,从而影响嘌呤和嘧啶代谢,通过抑制炎症细胞的增殖来达到抗炎的作用。

甲氨蝶呤给药方式探讨

甲氨蝶呤是一种人工合成化合物,为叶酸结构类似物,通过竞争性地抑制二氢叶酸(FH2)与二氢叶酸还原酶(DHFR)的结合,降低细胞内可被利用的亚叶酸(FH4)含量,从而影响嘌呤和嘧啶代谢,通过抑制炎症细胞的增殖来达到抗炎的作用。

甲氨蝶呤除了治疗类风湿性关节炎外,在特发性炎性肌病、银屑病性关节炎、系统性红斑狼疮、系统性血管炎、系统性硬化症等风湿病治疗中均具有很高地位。

甲氨蝶呤用于治疗类风湿性关节炎最早可追溯到1951年,2018年类风湿性关节炎诊疗指南更是强调甲氨蝶呤是类风湿性关节炎治疗的锚定药物,可见其在类风湿性关节炎治疗中的地位。

甲氨蝶呤是类风湿性关节炎治疗锚定药物,虽然其应答程度不及肿瘤坏死因子,但其经济实惠及确定的疗效,使类风湿关节炎病友获益更多。

研究表明,甲氨蝶呤能显着改善所有临床疾病变量,如关节肿胀、压痛数量,关节功能状态、医患的总体评价(VAS)以及炎症反应物(超敏C反应蛋白、红细胞沉降率)等,提高生活质量及生存率。治疗基线时没有侵蚀性病变的病友获益更多,经正规治疗后大多数病友不会出现关节侵蚀。

不同给药途径的优劣

甲氨蝶呤主要通过口服、肌内注射和皮下注射三个途径给药。

口服甲氨蝶呤的吸收程度在治疗类风湿性关节炎所用剂量范围内变化很大,口服甲氨蝶呤每周7.5mg的剂量比15-20mg的剂量吸收更好。使用更高的剂量时,生物利用度下降可能更加突出,使用超过每周25mg的甲氨蝶呤时生物利用度下降甚至达1/3。

为了达到更多药物达到血液,发挥更佳疗效及减少不良反应,肌肉注射、皮下注射两个途径更佳,然而国内尚没有普及此类型制剂用于治疗类风湿性关节炎。个案观察结果支持皮下给药或肌内注射可避免肠道毒等副反应,但缺少正式试验比较过不同给药途径的安全性、耐受性或有效性。

对于出现重度关节破坏的晚期类风湿性关节炎病友,由于存在手指灵活度降低,甚至由于视力、认知功能受损,口服剂型可能是最佳剂型。

甲氨蝶呤最佳治疗剂量

由于个体差异,甲氨蝶呤的毒性副作用无法预测。对于国人,在肾功能正常者每周推荐剂量10mg~15mg,2018年中国类风湿性关节炎诊疗指南指出我国人群小剂量甲氨蝶呤(≤10mg/周)的不良反应轻、长期耐受性较好。

对不良反应敏感或者老年病友,临床治疗中可从每周甲氨蝶呤7.5mg起,根据耐受情况和病情需要增加甲氨蝶呤剂量,可在治疗开始4周后以每周增量2.5mg逐步达到理想剂量。当然,对于年轻、体重较大、病情高度活动者,每周起始剂量可以直接达15mg。

对不良反应较敏感病友还可以尝试分次给药,将甲氨蝶呤单次剂量分成2份,间隔12小时给药一次,同样是一天内完成用药。不仅提高对不良反应的耐受性,还可以提高每次给药的生物利用度。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647481, encodeId=0034164e48173, content=<a href='/topic/show?id=e23fe88573b' target=_blank style='color:#2F92EE;'>#给药方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78857, encryptionId=e23fe88573b, topicName=给药方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcb423427361, createdName=doctorzheng, createdTime=Sat Jun 08 22:17:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265819, encodeId=57601265819f2, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334079, encodeId=546b13340e96b, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597367, encodeId=8f8e159e36770, content=<a href='/topic/show?id=fa1710082017' target=_blank style='color:#2F92EE;'>#风湿关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100820, encryptionId=fa1710082017, topicName=风湿关节炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=456818510265, createdName=xuruicheng, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647481, encodeId=0034164e48173, content=<a href='/topic/show?id=e23fe88573b' target=_blank style='color:#2F92EE;'>#给药方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78857, encryptionId=e23fe88573b, topicName=给药方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcb423427361, createdName=doctorzheng, createdTime=Sat Jun 08 22:17:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265819, encodeId=57601265819f2, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334079, encodeId=546b13340e96b, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597367, encodeId=8f8e159e36770, content=<a href='/topic/show?id=fa1710082017' target=_blank style='color:#2F92EE;'>#风湿关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100820, encryptionId=fa1710082017, topicName=风湿关节炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=456818510265, createdName=xuruicheng, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-17 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647481, encodeId=0034164e48173, content=<a href='/topic/show?id=e23fe88573b' target=_blank style='color:#2F92EE;'>#给药方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78857, encryptionId=e23fe88573b, topicName=给药方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcb423427361, createdName=doctorzheng, createdTime=Sat Jun 08 22:17:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265819, encodeId=57601265819f2, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334079, encodeId=546b13340e96b, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597367, encodeId=8f8e159e36770, content=<a href='/topic/show?id=fa1710082017' target=_blank style='color:#2F92EE;'>#风湿关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100820, encryptionId=fa1710082017, topicName=风湿关节炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=456818510265, createdName=xuruicheng, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647481, encodeId=0034164e48173, content=<a href='/topic/show?id=e23fe88573b' target=_blank style='color:#2F92EE;'>#给药方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78857, encryptionId=e23fe88573b, topicName=给药方式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcb423427361, createdName=doctorzheng, createdTime=Sat Jun 08 22:17:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265819, encodeId=57601265819f2, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334079, encodeId=546b13340e96b, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597367, encodeId=8f8e159e36770, content=<a href='/topic/show?id=fa1710082017' target=_blank style='color:#2F92EE;'>#风湿关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100820, encryptionId=fa1710082017, topicName=风湿关节炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=456818510265, createdName=xuruicheng, createdTime=Wed Oct 17 06:17:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]

相关资讯

Gastroenterology:实现治疗响应的溃疡性结肠炎患者可停止甲氨蝶呤持续治疗

研究认为,对于已经实现无类固醇治疗响应的溃疡性结肠炎患者,持续的甲氨蝶呤治疗意义不显著

Nature:癌症食疗再添依据!常见氨基酸可显著提高化疗效果

癌症是人类的一大顽疾。为了攻克癌症,科学家们一边在寻找全新的疗法,一边在尝试让现有的抗癌药物变得更有效。

Ann Rheum Dis:类风湿性关节炎患者托珠单抗或联合甲氨蝶呤治疗缓解后的托珠单抗停药

在一半以上的患者中,托珠单抗停药后的持续低疾病活动性可以通过继续使用甲氨喋呤得到维持。重新使用托珠单抗使超过90%的患者得到缓解。

PLos One:RA患者MTX治疗期间肝活检中的非酒精性脂肪性肝炎样类型

RA低剂量MTX治疗期间,NAFLD/NASH与肝损伤之间的风险因素和组织学发现相似,这表明两种疾病之间存在紧密关联。

Ann Rheum Dis:类风湿性关节炎患者甲氨蝶呤治疗反应不足的临床预测因子

在DMARD初治的新发RA患者中,更高的DAS28、目前吸烟和不饮酒是对“MTX+”升阶梯疗法反应不足的预测因子。

2018 甲氨蝶呤治疗幼年特发性关节炎建议

少年特发性关节炎常规治疗药物由非生物、疾病修饰的抗风湿药物组成,最常应用的药物为甲氨蝶呤。本文主要针对应用甲氨蝶呤治疗幼年特发性关节炎提出指导建议,内容涉及甲氨蝶呤的安全性和有效性,治疗剂量,减量和停药,叶酸的补充等。